Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

David A. Hyman, MD, JD, on Inclusive Shared Savings

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement




Dec
18
Today In Oncology
Community Oncology Report Showcases Barriers to Therapy Access, Staffing, and Clinical Trial Participation
FDA Approves CAR T-Cell Therapy for Relapsed/Refractory Marginal Zone Lymphoma
Addition of Eflornithine to Lomustine in Patients With Recurrent Grade 3 Astrocytoma
Preoperative PAXG vs mFOLFIRINOX in Pancreatic Ductal Adenocarcinoma
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced NSCLC
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo